Cite
HARVARD Citation
Israelsen, S. et al. (2021). Comparable COVID‐19 outcomes with current use of GLP‐1 receptor agonists, DPP‐4 inhibitors or SGLT‐2 inhibitors among patients with diabetes who tested positive for SARS‐CoV‐2. Diabetes, obesity & metabolism. 23 (6), pp. 1397-1401. [Online].